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Cancer diagnosis in Scottish primary care: results from the National Cancer Diagnosis Audit  
ABSTRACT 
Background 
The UK has poorer cancer survival than some other developed countries. UK diagnostic intervals may 
be longer and health service organization, which differs between UK countries could be a determining 
factor. The National Cancer Diagnosis Audit explored primary care cancer diagnosis in Scotland and 
England.   
Aim 
To describe cancer diagnosis in Scottish primary care and draw some comparisons with cancer 
diagnostic activity in England.  
Design and setting 
National clinical audit of cancer diagnosis in Scottish and English general practice. 
Method 
Participating GPs collected diagnostic pathway data on patients diagnosed in 2014 from medical 
records. Data were supplemented by linkage to national cancer registries. Analysis explored and 
compared patient characteristics, diagnostic intervals, and routes to diagnosis.  
Results 
7.7% of all Scottish general practices in 2017 provided data on 2,014 cancer diagnoses. 71.5% of cases 
presented to GPs and 37.4% were referred using the “Urgent-Suspected Cancer” route. The median 
primary care interval was 5 days (IQR 0-23 days) and median diagnostic interval was 30 days (IQR 13-
68). Both varied by cancer-site. Diagnostic intervals were longer in the most remote patients and those 
with more comorbidities. The Scottish and English samples corresponded closely in key characteristics.  
Conclusions 
Most people diagnosed with cancer in Scotland present to a GP first. Most are referred and diagnosed 
quickly, with variations by cancer-site. Intervals were longest for the most remote patients. GPs in 
Scotland and England appear to perform equally but, in view of growing differences between health 
systems, future comparative audits may be informative. 
 
WORD COUNT: 249 
MAIN TEXT WORD COUNT: 3247  
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INTRODUCTION 
Poorer UK cancer outcomes compared to elsewhere are attributed to longer diagnostic intervals[1-4]. 
The first English National Audit of Cancer Diagnosis in Primary Care undertaken in 2009/10 and 
published in 2011 provided new insights into cancer diagnosis, and influential outputs on primary 
care’s role in improving cancer outcomes[5]. Consequent policy and research aims to reduce primary 
care cancer intervals[6]. These include referral guidelines, public education campaigns and service 
initiatives, such as providing general practitioners (GPs) with direct access to their patients’ imaging 
and endoscopy results[7-9]. 
Evaluation, implementation and re-evaluation should underpin modern healthcare delivery[10]. In 
2016-17, Cancer Research UK, together with NHS partners, the Royal College of General Practitioners 
(RCGP) and Macmillan Cancer Support, conducted a second National Cancer Diagnosis Audit (NCDA), 
this time including Scotland[11]. Scotland and England face similar challenges in providing publicly-
funded health services to ageing populations. Like England, Scotland has relatively poor cancer 
outcomes compared to other developed nations[12,13].  
The Scottish NHS is wholly devolved with some important and evolving differences in funding, 
organization and delivery compared to England[14,15]. For example per-capita spend on the NHS is 
higher in Scotland[15]. Furthermore, the Scottish Government’s 2020 vision emphasises integrated 
health and social care, shifting the balance of care from hospitals to communities[16]. In England, 
clinical commissioning groups buy services for localities (including investigations like endoscopy) from 
competing service providers[17]. Cancer referral guidelines also increasingly differ between Scotland 
and England[18-20]. 
The NCDA is conducted to improve understanding of primary care cancer diagnosis across all 
constituent countries of the UK. This study was based upon the Scottish data and had two objectives. 
First, to describe the Scottish NCDA data and enable an understanding of how Scottish GPs are 
currently diagnosing cancer. The second objective was to conduct a top-line comparison with the 
published English NCDA data with respect to route to diagnosis, prolonged diagnostic pathway 
intervals and avoidable delays in primary care. This is an important question since it is currently 
unknown whether growing divergence between the Scottish and English NHS, as described above, is 
differentially affecting the relative experience of people diagnosed with cancer in the two countries,. 
 
METHODS  
Data for this study were produced and managed by the Information Services Division (ISD) Scotland, 
which provides health information and intelligence to support quality improvement and decision 
making in healthcare. Scottish participation in the NCDA was first approved following application to 
the Public Benefit and Privacy Panel (PBPP) of NHS Scotland, a patient advocacy panel which 
scrutinises applications for access to NHS Scotland health data for non-direct care. 
Following PBPP authorization ISD assigned all incident cancer cases in 2014 (excluding non-melanoma 
skin cancer) to the patient’s registered general practice at diagnosis using the Scottish Cancer Registry. 
NCDA participants were then volunteer practices which were recruited following promotion by the 
RCGP, Cancer Research UK, and Macmillan Cancer Support. Practices agreeing to participate in NCDA 
underwent a registration process which included the signing of Caldicott Data Release Forms. This 
allowed the practice to share data about individual patients held on electronic primary care records 
with ISD, to be linked there to centrally-held data from the Scottish Cancer Registry.. The approved 
Cancer diagnosis in Scottish primary care – REVISION 1 – 20/01/20 
practice lead (usually a GP) was securely sent pre-prepared Excel data-collection forms for eligible 
cancer diagnoses during 2014. Practices returned de-identified forms to the ISD using secure NHS 
email. Forms were issued and returned between February and June 2017. Forms sought data on 
patient demographics including co-existing conditions, diagnostic pathways and dates and details of 
route to diagnosis. Participating GPs subjectively judged whether, in hindsight, they perceived 
“avoidable delay” in diagnosis. Participating GPs were also asked to judge if they perceived that safety-
netting had been employed during the diagnostic pathway – i.e. evidence that tests and/or follow-up 
GP appointments had been used in the context of diagnostic uncertainty to monitor patients until 
sufficient evidence had accrued to support onward referral to secondary care.   Stage and grade at 
diagnosis was pre-populated from Scottish Cancer Registry data. Residential postcodes were used to 
assign the relevant Scottish Index of Multiple Deprivation (SIMD) quintile to each individual cancer 
patient[21]. Geographical place of residence was also assigned using the Scottish Government two-
fold Urban-Rural Classification category which designates individuals living in an area with a 
population of less than 3000 as rural, and those in a settlement with more than 300 residents as 
urban[22].  
Key variables detailing route to diagnosis, pathway intervals, avoidable delays, investigations and 
safety-netting were grouped by sex, age-group, and cancer-site. Primary care-led investigations were 
grouped into blood, urinary, imaging, endoscopy, and other tests. The number of separate co-existing 
medical conditions that each participant had been diagnosed with was provided from the primary 
care-held medical record and was were categorised into a comorbidity count of 0, 1-2, and 3 or more. 
Analysis focused on two key intervals in the diagnostic pathway: primary care interval (PCI) and 
diagnostic interval (DI)[23] Both intervals were calculated using two dates derived from the primary 
care-held electronic record and the date of diagnosis recorded in the Scottish Cancer Registry.:. PCI 
was defined and calculated as days from date of first presentation in primary care with symptoms 
relevant to the final cancer diagnosis, to date of first referral from primary care. DI was defined as 
days from date of first relevant presentation in primary care to date of diagnosis recorded in the 
Scottish Cancer Registry. Interval times of <0 and >730 days were excluded to minimise the effect data 
errors and difficult interpretation[24]. Medians (Inter-quartile-range) are described, along with 
percentage of patients with a PCI or DI >60 or 90 days. 
In order to compare Scottish and English NCDA data only published summary English data were 
available to the current analysis[24]. Thus, some simple significance tests on proportions of binary 
variables were possible, but continuous variables such as diagnostic intervals could not be statistically 
compared. Summary data on routes to diagnosis, prolonged diagnostic pathway intervals and 
avoidable delays in primary care were abstracted from the published paper reporting the analysis of 
the English NCDA[24].The relative distribution of  diagnostic route, PCI and DI < 60 and 90 days, and 
avoidable delays were described using contingency tables with stratification for gender. The statistical 
significance of differences, were compared between England and Scotland using  the Chi-squared 
test[24].  
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RESULTS 
Participation rates and characteristics of the sample 
Seventy-three Scottish general practices (7.7% of all Scottish general practices in 2017) submitted data 
on 2,014 cancer diagnoses (6.3% of cancers diagnosed in Scotland, 2014). The mean list size of Scottish 
practices participating in the NCDA was 5996 patients compared to 6171 for Scottish general practices 
overall. The supplementary table 5 shows the proportion of practices corresponding to each SIMD 
deprivation quintile and to the 2-fold and 6-fold Urban-Rural classifications based on the practices’ 
postcode.   Median age of included patients was 70 years and 50.4% were female (table 1). Of included 
cases 17.8% were lung cancers, 13.4% breast cancers, 11.0% prostate cancers, 9.1% colon cancers and 
4.4% rectal cancers. Stage at diagnosis was available for 59.8%. Patients with white ethnicity 
comprised 99.2% of the sample and 98.1% were native English speakers (table 2). With respect to 
personal circumstances 39.4% were living alone, 11.9% lived in a care home or were housebound and 
16.0% had communication difficulties (table 2). The commonest co-morbidities were hypertension 
(38.0%), cardiovascular disease (23.0%) and arthritis/musculoskeletal disease (18.2%) (table 2). 
Overall, 25.1% had no comorbidities and 21.7% had three or more. Almost a quarter (23.1%) of the 
sample were from the most-deprived SIMD quintile with 18.8% from the least deprived. With respect 
to geographical place of residence 76.4% were urban-dwelling and 23.6% were rural-dwelling, which 
is representative of Scotland as a whole (table 2)[25]. 
Presentations and referrals 
Of the whole sample, 87.1% presented clinically with 71.5% presenting initially to a GP (62.9% GP 
surgery; 7.1% GP home visit; 1.2% GP out-of-hours service; 0.3% other primary care facility). Initial 
presentation at Accident and Emergency accounted for 3.7% of the sample. 
The “Urgent – Suspected Cancer” (USC) referral route was used in 37.4% of cases, although there was 
a a marked range in the proportion of cases that had been diagnosed following a USC referral by 
cancer-site. For example, over 50% of breast (53.3%), oesophageal ((54.0%) and melanoma (53.2%) 
cases had been referred via the USC route, whereas only 20% of pancreatic, 9.5% of multiple myeloma 
and 12.5% of liver cancer cases had followed the USC route route. Overall 20% (n=402) of patients 
were diagnosed after an emergency presentation (either the patient was admitted to hospital by a GP 
or self-presented at an Accident and Emergency department), ranging from 69.6%, 55.4%, 49.1% and 
38.6% for brain, liver, pancreatic and ovarian cancers to 5% or less  for oral, breast and melanoma. 
Intervals and avoidable delays 
Median PCI was 5 days (IQR 0-23 days), with 11.3% of patients having a PCI longer than 60 days and 
7.7% longer than 90 days (table 3a). Overall, females had a shorter median PCI than males, 2 versus 8 
days. The longest median PCIs were 13.5 days for lung cancer and 15.5 days for prostate cancer. The 
median DI was 30 days (IQR 13-68 days) overall, 27 days for females and 34 days for males (table 3b). 
The median DI was longest for prostate cancer (58 days) and shortest for liver cancer (6 days). Overall 
28.3% of patients had a DI longer than 60 days and 17.8% longer than 90 days. In 36.0% of renal cancer 
patients the DI was longer than 90 days compared to just 2.7% of breast cancer patients. The 
proportion of patients with PCIs and DIs beyond 60 and 90 days also appeared to be higher in those 
with more than three comorbidities compared to those with none or fewer.  
Median PCI was 4 days for the most deprived patients compared to 5 days for the least deprived and 
corresponding figures for DI were 26.5 days versus 34 days. Using the Rural-Urban 2-fold classification 
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rural patients had a median PCI of 7 days versus 4 days for urban patients, with corresponding media 
DIs of 34 versus 29 days. 
Overall, perceived avoidable delay was reported in 29.1% of cases ranging from 40.9% of oral cancer 
cases to 17.0% of pancreatic and 14.0% of liver cancer cases (table 4). There was little variation in the 
proportion of cases judged to have had an avoidable delay across deprivation categories, but 33.1% 
of rural patients versus 27.7% of urban patients were judged to have been subject to avoidable delay 
at some point in their pathway to diagnosis. 
Investigations and safety netting 
Overall 49.0% of cases had no investigations initiated in primary care, ranging from 95.1% and 83.3% 
of breast and melanoma cases to 19.0% of myeloma cases (table 5). In patients referred by their 
practice, but not at the first consultation, there was evidence of primary care safety netting recorded 
in the patients’ notes at the index consultation in 62.3%, ranging from 85.7% and 81.5% in myeloma 
and pancreatic cancer to 43.2% and 27.8% for other gynaecological (cervical; vulval; vaginal, and 
endometrial) and melanoma (table 6). 
Comparing proportions in the Scottish and English samples 
A comparison of summary data from the Scottish and English NCDA samples are shown in 
supplementary tables S1-4..  The Scottish sample was 11.8% of the size of the English sample and 
comprised data from approximately 7.7% of all general practices and 6.3% of all cancers diagnosed in 
Scotland in 2014. The figures for the English sample were 5.0% and 5.7% respectively. Table S1 shows 
that the samples corresponded closely with respect to gender, age and cancer-sites. Table S2 
compares key patient characteristics of the two samples, showing that cancer stage data were less 
complete in the Scottish sample. Most other patient characteristics were comparable. In England, 
51.8% of relevant patients were referred via the 2WW pathway compared to 37.4% using the 
analogous USC pathway in Scotland (p<0.001). In both Scotland and England, the median PCI was 5 
days and there were no significant differences in the proportion of patients with a PCI of more than 
60 or 90 days. In Scotland, the median DI was 30 days (IQR 13-68), compared to 40 days in England 
(IQR 15-86). There was a significantly lower proportion of Scottish patients with a DI of more than 60 
(28.3% versus 35.8%, p<0.001) and 90 days (17.8% versus 24.0%, p<0.001). Overall 29.1% of cases in 
Scotland were subject to avoidable delay as judged by the GP, compared to 22.0% in England, the 
difference being non-significant (p=0.239). In Scotland 3.1% of cases had an endoscopy initiated in 
primary care compared to 1.6% in England (p<0.001). 
 
DISCUSSION 
Summary of key findings 
Most included Scottish patients were diagnosed following symptomatic presentation to a GP, about 
one-third via an “Urgent-Suspected Cancer” referral. About one-fifth were diagnosed following 
emergency presentation. The median PCI was 5 days with variation by cancer-site. The PCI was longest 
for prostate and lung cancer, and shortest for melanoma, other gynaecological and liver cancer. This 
likely reflects a spectrum in symptom specificity at presentation, but also that some cancers are 
usually diagnosed following positive tests in primary care. Further, active monitoring, with serial PSA 
testing, is appropriate to diagnose prostate cancer. This fact will also have contributed to the longer 
median PCIs and DIs for males compared to females. Higher proportions of remote patients and those 
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with more than three comorbidities also appeared to have PCI and DI’s longer than 60 days. GP-judged 
avoidable delays varied by cancer-site and were more frequent in remote patients. 
Although only 11.8% as large as the English NCDA 2014 dataset, the Scottish dataset comprised 
demographically similar patients drawn from a representative spread of Scottish general practices. 
There were statistically significant differences in the proportions of diagnostic routes used between 
the two countries with Scottish GPs using the urgent suspected cancer route less frequently, but 
appearing to have significantly easier access to endoscopic diagnostic modalities. There was also a 
significant difference in the proportion of English patients reported to have an overall diagnostic 
interval longer than 60 or 90 days. It was not possible to statistically compare PCI and DI in the two 
samples, although the simple observation that median PCI was identical and median DI only 10 days 
more in England implies that, despite differences in health service organization cancer diagnostic 
pathways do not meaningfully diverge between Scotland and England. Nevertheless, in view of 
divergence between these neighbouring healthcare systems it may be wise to make future formal 
comparisons. 
Context with other literature 
Data on 2,014 new primary cancer diagnoses throughout Scotland in 2014 are reported, 
approximately 6% of the total. There is striking similarity in sample composition with the, albeit larger, 
English NCDA sample[24]. Notably PCI, most sensitive to GP’s actions, is unlikely to differ statistically. 
[26-28]. 
The proportion of English diagnoses via urgent (2WW) referrals made is significantly higher than in 
Scotland (USC), the difference apparently made up by more non-specific urgent referrals and 
emergency presentations in Scotland.[24] Of note, in 2014 when NCDA cases in both countries were 
diagnosed, Scottish and English GPs used different suspected cancer referral guidelines[29]. Scottish 
guidelines arguably, allow the consulting GP more latitude to interpret the clinical scenario presented 
before arriving at the decision as to whether a USC referral should be made. On the other hand the 
English guidelines implicitly mandated a 2WW referral when the presentational symptom signature 
reached an approximate 5% risk of cancer[30-32]. in 2015, in the revised English guidelines this was 
tightened to an explicit 3% risk of cancer[18], an approach not adopted in the revised Scottish 
guidelines of 2019[33]. Further, English GP practices are compared annually in PHE practice profiles, 
the value of which are questioned, and which are not adopted by Scottish Government[29]. 
Additionally, and despite well-publicised initiatives in England, it appeared that Scottish GPs reported 
greater direct access to key diagnostic modalities, such as endoscopies[8]. It could be important to 
understand how clinical commissioning affected the relative ordering of investigations by GPs in 
Scotland and England. 
The comparison between Scotland and England used data from two national samples that can be 
demonstrated to be demographically similar. The analysis shows slightly longer overall diagnostic 
intervals in England compared to Scotland, but these cannot be statistically verified in the current 
dataset. An international analysis of diagnostic delay in colorectal cancer, which pooled data from 
several different countries, suggests prolonging diagnostic intervals by even a few days can have a 
negative impact on cancer outcomes[34]. Consequently, if the difference seen in diagnostic 
performance in this study is real it could lead to a worsening in cancer outcomes in England compared 
to Scotland. Equally, it is possible the differences observed are caused by systematic differences in the 
way in which key dates are defined and recorded between Scotland and England [35]. In either case, 
and given that the English and Scottish health systems are evolving differently, it makes sense to 
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enable contemporaneous and combined comparative analysis in future iterations of the NCDA to 
detect increasing differences in cancer diagnostic performance which could be clinically important. 
 
Strengths and limitations 
The methodology underpinning data collection was robust, carefully developed and consistently 
applied in the two countries. There were some differences in the way data were collected: via an 
online portal for direct data entry in England compared to secure exchange of Microsoft Excel 
datasheets in Scotland. It is unlikely that this difference introduced any systematic difference in the 
data provided. Data were handled by highly qualified data professionals in both countries, and both 
datasets are largely complete and were subject to high-level quality assurance and data cleaning.  
Data were collected by GPs or practice staff themselves arguably, admitting bias in recording details 
reflecting negatively on practices. On the other hand, practices were allocated cases centrally and 
could not selectively disregard those where intervals had been prolonged. It is possible that the 
practices which chose to take part in the audit were not typical and less likely to be poor performers. 
Against this, the English researchers reported data demonstrating the typicality of participant 
practices and the Scottish practices too were drawn from a representative spread of list-size, practice 
location and deprivation (Supplementary table 5). Finally, the data in both samples were obtained 
from cancer diagnoses in a single year which raises the possibility that case-mix could affect the 
results[29]. It is also possible that external influences acting regionally (e.g. influenza outbreaks or 
staffing problems) could impact the observed results. Both facts emphasise the importance of 
repeated audit cycles to guide true quality improvement. Finally, this is a descriptive paper which uses 
high quality audit data from a representative sample of practices and patients to describe cancer 
primary care-based cancer diagnosis in Scotland. The conclusions and implications cannot be definitive 
and must be interpreted cautiously.   
 
Implications and conclusions 
Most Scottish people diagnosed with cancer present first to a GP and are referred quickly to secondary 
care. Intervals vary for different cancers sites, likely reflecting differential presentation and 
investigation within Scottish primary care. Key intervals appeared longer for the most remote patients 
and for those with three or more comorbidities, which will be explored in future research. 
GPs in Scotland and England appear to diagnose cancer equally well. A longer median diagnostic 
interval in England is not statistically supported and may be an artefact of differences in data 
collection. Alternatively, the difference could be real, and growing differences between Scotland and 
England’s healthcare culture and delivery could lead to significant differences in important patient 
outcomes in future. Consequently, regular and robust audits comparing cancer diagnosis in the UK 
nations should be considered.  
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TABLE 1: SAMPLE COMPOSITION AND REFERRAL TYPE THAT LED MOST DIRECTLY TO THE CANCER DIAGNOSIS (n=2014) 
 TOTAL OF NCDA 
ENGLAND n(%) 

























TOTAL 17042 2014 753 (37.4) 186 (9.2) 207 (10.3) 119 (5.9) 402 (20.0) 22 (1.1) 167 (8.3) 158 (7.8) 
GENDER           
MALE 8544 (50.1) 998 (49.6) 357 (35.8) 93 (9.3) 125 (12.5) 27 (2.7) 203 (20.3) 13 (1.3) 97 (9.7) 83 (8.3) 
FEMALE 8498 (49.9) 1016 (50.4) 396 (39.0) 93 (9.2) 82 (8.1) 92 (9.1) 199 (19.6) 9 (0.9) 70 (6.9) 75 (7.4) 
AGE GROUP 
(YEARS) 
          
0-24 198 (1.2) 17 (0.8) 1 (5.9) 2 (11.8) 2 (11.8) 0 (9) 4 (23.5) 0 (0) 3 (17.6) 5 (29.4) 
25-49 1705 (10.0) 184 (9.1) 69 (37.5) 19 (10.3) 25 (13.6) 13 (7.1) 27 (14.7) 3 (1.6) 19 (10.3) 9 (4.9) 
50-64 4144 (24.3) 522 (25.9) 190 (36.4) 60 (11.5) 59 (11.3) 54 (10.3) 79 (15.1) 5 (1.0) 38 (7.3) 37 (7.1) 
65-74 4877 (28.6) 564 (28.0) 226 (40.1) 42 (7.4) 63 (11.2) 41(7.3) 101 (17.9) 10 (1.8) 38 (6.7) 43 (7.6) 
75-84 4213 (24.7) 520 (25.8) 198 (38.1) 45 (8.7) 43 (8.3) 10 (1.9) 24.4 (127) 4 (0.8) 49 (9.4) 44 (8.5) 
>84 1905 (11.2) 207 (10.3) 69 (33.3) 18  (8.7) 15 (7.2) 1 (0.5) 64 (30.9) 0 (0) 20 (9.7) 20 (9.7) 
CANCER-SITE           
Bladder 490 (2.9) 50 (2.5) 23 (46.0) 7 (14.0) 5 (10.0) 0 (0) 7 (14.0) n<5 n<5 n<5 
Brain 265 (1.6) 23 (1.1) 0 (0) n<5 0 (0) 0 (0) 16 (69.6) 0 (0) n<5 n<5 
Breast 2714 (15.9) 270 (13.4) 144 (53.3) 19 (7.0) 13 (4.8) 63 (23.3) 5 (1.9) n<5 14 (5.2) 9 (3.3) 
Cancer of 
Unknown Primary 
400 (2.3) 29 (1.4) n<5 5 (17.2) 0 (0) n<5 13 (44.8) 0 (0) n<5 3 (10.3) 
Colon 1320 (7.7) 183 (9.1) 47 (25.7) 12 (6.6) 13 (7.1) 22 (12.0) 59 (32.2) n<5 16 (8.7) 13 (7.1) 
Leukaemia 470 (2.8) 44 (2.2) 7 (15.9) 8 (18.2) n<5 n<5 13 (29.5) 0 (0) 8 (18.2) n<5 
Liver 272 (1.6) 56 (2.8)  7 (12.5) n<5 n<5 n<5 31 (55.4) 0 (0) 8 (14.3) n<5 
Lung1 2132 (12.5) 359 (17.8) 134 (37.3) 33 (9.2) 21 (5.8) n<5 109 (30.4) 0 (0) 35 (9.7) 26 (7.2) 
Lymphoma 739 (4.3) 78 (3.9) 30 (38.5) 11 (14.1) 10 (12.8) n<5 16 (20.5) n<5 n<5 5 (6.4) 
Melanoma 836 (4.9) 79 (3.9) 42 (53.2) 10 (12.7) 17 (21.5) n<5 n<5 0 (0) 7 (8.9) n<5 
Multiple 
Myeloma 
272 (1.6) 21 (1.0) n<5 0 (0) n<5 0 (0) 7 (33.3) 0 (0) n<5 6 (28.6) 
Oesophageal 447 (2.6) 63 (3.1) 34 (54.0) 9 (14.3) 6 (9.5) n<5 9 (14.3) 0 (0) n<5 n<5 
Oral 268 (1.6) 51 (2.5) 22 (43.1) 5 (9.8) 6 (11.8) 0 (0) n<5 n<5 6 (11.8) 7 (13.7) 
Other 1582 (9.3) 96 (4.8) 24 (25.0) 10 (10.4) 14 (14.6) 0 (0) 19 (19.8) n<5 7 (7.3) 21 (21.9) 
Other Gynae 607 (3.6) 83 (4.1)   33 (39.8) 14 (16.9) 11 (13.3) 10 (12.0) 7 (8.4) 0 (0) n<5 6 (7.2) 
Ovarian 332 (1.9) 38 (1.9) 12 (31.6) n<5 n<5 0 (0) 14 (38.6) n<5 n<5 n<5 
Pancreatic 2130 (2.7) 55 (2.7) 11 (20.0) n<5 n<5 n<5 27 (49.1)  0 (0) n<5 6 (10.9) 
Prostate 2130 (12.5) 222 (11.0) 95 (42.8) 17 (7.7) 56 (25.2) n<5 15 (6.8) 6 (2.7) 14 (6.3) 18 (8.1) 
Rectal2 648 (3.8) 88 (4.4) 41 (46.6) 7 (8.0) 9 (10.2) 13 (14.8) 6 (6.8) n<5 10 (11.4) n<5 
Renal 557 (3.3) 71 (3.5) 23 (32.4) 5 (7.0) 5 (7.0) n<5 13 (18.3) n<5 13 (18.3) 9 (12.7) 
Stomach 308 (1.8) 55 (2.7) 18 (32.7) 5 (9.1) 6 (10.9) 0 (0) 13 (23.6) n<5 n<5 7 (12.7) 
1 Lung cancer cases includes  ICD codes C30 and C32 
2 Rectal cancer cases includes ICD code C21
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TABLE 2: Patient Characteristics 
 SCOTLAND ENGLAND 
 N (%) N (%) 
CANCER STAGE     
0 0 0 13 0.1 
1 270 22.4 4255 32.6 
2 262 21.7 2872 22.0 
3 250 20.7 2412 18.5 
4 423 35.1 3506 26.8 
Unknown 809  3984  
ETHNICITY     
Asian 8 0.4 385 2.6 
Black 0 0 156 1.1 
Mixed 0 0 134 0.9 
White 1824 99.2 13850 95.0 
Other 7 0.4 49 0.3 
Not known 66  1462  
Screening 109  1006  
LANGUAGE     
Native English speaker 1808 98.1 14251 95.3 
English is not the patient's mother tongue but they are very fluent in 
English 
27 1.5 452 3.0 
English not mother tongue and patient not fluent in English 8 0.4 257 17 
Not known 62  1076  
Screening 109  1006  
COMMUNICATION DIFFICULTY     
No difficulty 1481 84.0 12326 89.6 
Speech impairment 14 0.8 97 0.7 
Hearing impairment 100 5.7 440 3.2 
Vision impairment 46 2.6 194 1.4 
Learning difficulty 9 0.5 94 0.7 
Language barrier 9 0.5 169 1.2 
Severe longstanding mental illness 13 0.7 86 0.6 
Cognitive impairment 84 4.8 495 3.6 
Other 7 0.4 45 0.3 
Not known 142  2276  
Screening 109    
HOUSEBOUND STATUS     
The patient is not considered housebound 1562 88.1 12997 89.0 
The patient is considered housebound 174 9.8 1263 8.7 
Lives in residential/nursing care home 37 2.1 340 2.3 
Not known 132  1436  
Screening 109  1006  
LIVING ARRANGEMENT     
Co-habiting 993 67.2 8749 72.2 
Living alone 435 29.4 2834 23.4 
In residential or nursing home 50 3.4 530 4.4 
Not known 427  3923  
Screening 109  1006  
NUMBER OF COMORBIDITIES     
None 422 22.3 3801 24.3 
One Comorbidity 537 28.4 4721 30.2 
Two Comorbidities 469 24.8 3756 24.0 
Three or More Comorbidities 411 21.7 3355 21.5 
Unknown 13  403  
Screening 109  1006  
TYPE OF COMORBIDITY     
No Comorbidity 422 22.3 3801 24.3 
Hypertension 719 38.0 5914 37.8 
Cardiovascular Disease 436 23.0 3230 20.7 
Arthritis/Musculoskeletal Disease 344 18.2 2769 17.7 
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Diabetes 257 13.6 2463 15.8 
Chronic Obstructive Pulmonary Disease 295 15.6 2342 15.0 
Previous Cancer 193 10.2 1763 11.3 
Cerebrovascular Disease 163 8.1 1083 6.9 
Cognitive Impairment 99 4.9 688 4.4 
Severe Longstanding Mental Illness 50 2.6 385 2.5 
Longstanding Physical Disability 29 1.5 257 1.6 
Other Comorbidity 453 23.8 3094 19.9 
Not Known 13  403  
Screening 109  1006  
REGIONAL CANCER NETWORK     
North 682 35.8   
West 1013 53.2   
South East 210 11.0   
Screening 109    
SIMD22     
1 (Most Deprived) 441 23.1   
2 351 18.4   
3 323 17.0   
4 431 22.6   
5 (Least Deprived) 359 18.8   
Screening 109    
URBAN-RURAL 6-FOLD CLASSIFICATION     
Large Urban Area 742 39.0   
Other Urban Area 446 23.4   
Accessible Small Town 194 10.2   
Remote Small Town 73 3.8   
Accessible Rural Area 214 11.2   
Remote Rural Area 236 12.4   
Screening 109    
URBAN-RURAL 2-FOLD CLASSIFICATION     
Urban 1455 76.4   
Rural 450 23.6   
Screening 109    
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Table 3a: Distribution of primary care interval by patient characteristics and cancer diagnosis groups1 
 N 25th centile, days Median, days 75th centile, days % >60 days % > 90 days 
TOTAL 1314 0 5 23 11.3 7.7 
GENDER       
Male 656 0.75 8 28 12.3 8.2 
Female 658 0 2 19 10.2 7.1 
AGE GROUP (YEARS)       
0-24 7 0 33 56 n<5 n<5 
25-49 122 0 1 22.5 8.9 5.6 
50-64 330 0 4 26 12.3 9.3 
65-74 374 0 7 27 12.0 8.5 
75-84 348 0 7 22 11.2 6.3 
>84 127 0 3 16 8.7 6.3 
CANCER-SITE       
Bladder 37 1 9 34.5 n<5 n<5 
Brain 7 0 10 49 n<5 0 
Breast 172 0 0 2 n<5 n<5 
Cancer of Unknown Primary 17 1.5 12 41 n<5 n<5 
Colon 97 0 5 20.5 12.2 9.2 
Leukaemia 27 1 10 48 n<5 n<5 
Liver 31 0 2 7 0 0 
Lung 222 1 13.5 41 17.6 9.5 
Lymphoma 62 0 6.5 27 11.3 n<5 
Melanoma 65 0 1 5.5 n<5 n<5 
Multiple Myeloma 10 0.75 12 57.75 n<5 n<5 
Oesophageal 55 0 7 25 12.7 10.9 
Oral 34 0 3.5 22.25 n<5 n<5 
Other 56 0 4 24 12.5 n<5 
Other Gynae 56 0 2 17.75 10.2 n<5 
Ovarian 23 0 13 39 n<5 0 
Pancreatic 35 0 4 54 n<5 n<5 
Prostate 160 6 15.5 41.75 13.8 11.9 
Rectal 65 0.5 4 23.5 10.8 10.8 
Renal 36 0 2.5 24.5 n<5 n<5 
Stomach 41 0 6 24 14.6 14.6 
NUMBER OF COMORBIDITIES       
None 326 0 3 24.5 10.4 7.7 
One Comorbidity 376 0 4 19 9.6 6.6 
Two Comorbidities 329 0 6 23 10.3 5.5 
Three of More Comorbidities 277 1 7 32.5 15.9 11.9 
REGIONAL CANCER NETWORK       
North 493 0 7 34 14.0 8.3 
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West 682 0 4 20 9.2 6.7 
South East 133 0 6 28.5 12.0 10.5 
SIMD22       
1 (Most Deprived) 284 0 4 19 9.8 8.0 
2 239 0 5 23 10.0 6.3 
3 224 1 6 27 10.2 7.6 
4 312 0 6 26 13.4 7.3 
5 (Least Deprived) 249 0 5 27 12.4 9.2 
URBAN-RURAL 6-FOLD CLASSIFICATION       
Large Urban Area 501 0 3 21 10.9 8.3 
Other Urban Area 290 0 4 20 9.3 4.8 
Accessible Small Town 145 1 8 32.5 12.3 8.2 
Remote Small Town 46 0.75 5.5 24.0 10.9 n<5 
Accessible Rural Area 156 0 7 24 9.6 7.0 
Remote Rural Area 170 0 7 33.25 16.5 11.8 
URBAN-RURAL 2-FOLD CLASSIFICATION       
Urban 982 0 4 22 10.6 7.1 
Rural 326 0 7 30 13.1 9.5 
 
1The primary care interval is restricted to 0-730 days with 40 cases being excluded as out with these limits. Patients with screen detected cancer are excluded. 
Primary care interval is available for patients where relevant valid dates are added.
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Table 3b: Distribution of diagnostic interval by patient characteristics and cancer diagnosis groups1 
 N 25th centile, days Median, days 75th centile, days % >60 days % > 90 days 
TOTAL 1572 13 30 68 28.3 17.8 
GENDER       
Male 788 13 34 74 31.5 19.3 
Female 776 13 27 61 25.1 16.3 
AGE GROUP (YEARS)       
0-24 11 0 16 78 n<5 n<5 
25-49 150 13,75 28 56.25 23.7 12.5 
50-64 388 13 32.5 73.75 30.8 20.8 
65-74 442 14 32 78.25 32.4 20.2 
75-84 407 13 30 63 25.5 16.2 
>84 166 7.5 24 54.25 22.3 13.3 
CANCER-SITE       
Bladder 43 26 47 63 27.9 11.6 
Brain 16 0 6 58 n<5 n<5 
Breast 187 14 21 29 5.9 2.7 
Cancer of Unknown Primary 22 1.75 14.5 48.25 18.2 n<5 
Colon 130 8.75 36 70.5 32.1 22.1 
Leukaemia 35 1 16 41 17.1 n<5 
Liver 41 1 6 20 16.3 n<5 
Lung 286 13 33 74.25 28.6 19.2 
Lymphoma 71 17 34 71 32.4 18.3 
Melanoma 72 13.25 28.5 49.75 19.4 12.5 
Multiple Myeloma 14 8.75 25 84.5 n<5 n<5 
Oesophageal 57 17 26 58.5 22.8 17.5 
Oral 41 13.5 35 80.5 36.6 19.5 
Other 72 13.25 30.5 66.75 30.6 16.7 
Other Gynae 60 13.25 28.5 49.75 31.7 19.0 
Ovarian 32 10.75 30 53.75 18.8 n<5 
Pancreatic 45 1 7 88 28.9 24.4 
Prostate 175 26 58 93 48.0 28.6 
Rectal 69 17.5 36 70.5 34.8 18.8 
Renal 50 12.5 43.5 110.5 46.0 36.0 
Stomach 46 18.5 42 99 37.0 26.1 
NUMBER OF COMORBIDITIES       
None 383 13 29 66 28.5 17.0 
One Comorbidity 451 12 28 60 23.9 16.0 
Two Comorbidities 393 13 30 71 28.2 16.0 
Three of More Comorbidities 337 13 33 86 34.4 23.7 
REGIONAL CANCER NETWORK       
North 578 14 34 81.25 32.6 21.0 
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West 826 13 28 60.25 24.9 14.7 
South East 160 15 36 81.25 30.6 22.5 
SIMD22       
1 (Most Deprived) 352 10.25 26.5 63 26.0 17.2 
2 295 14 30 70 28.7 16.9 
3 261 11 27 65 26.2 17.9 
4 356 14 32 78 31.6 19.3 
5 (Least Deprived) 300 15 34 68.75 28.6 17.6 
URBAN-RURAL 6-FOLD CLASSIFICATION       
Large Urban Area 594 12 29 67 27.8 17.8 
Other Urban Area 372 13 28 64 26.2 15.5 
Accessible Small Town 165 15 31 64 27.7 18.7 
Remote Small Town 53 12 24 67.5 29.6 14.8 
Accessible Rural Area 186 13.75 30 61 25.1 16.0 
Remote Rural Area 194 14.75 35.5 87 37.1 24.2 
URBAN-RURAL 2-FOLD CLASSIFICATION       
Urban 1184 13 29 66 27.4 17.0 
Rural 380 14 34 75.5 31.2 20.2 
 
1The diagnostic interval is restricted to 0-730 days with 61 cases being excluded as out with these limits. Patients with screen detected cancer are excluded. 
Diagnostic interval is available for patients where relevant valid dates are added.
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TABLE 4: Avoidable Delays (n=1669)1 
 AVOIDABLE DELAY n(%) NOT KNOWN n 
TOTAL 485 (29.1) 236 
GENDER   
Male 254 (29.9) 124 
Female 231 (28.2) 112 
AGE GROUP (YEARS)   
0-24 3 (27.3) 6 
25-49 49 (30.6) 15 
50-64 115 (28.0) 57 
65-74 148 (32.5) 72 
75-84 123 (27.3) 60 
>84 47 (26.0) 26 
CANCER-SITE   
Bladder 13 (27.7) 3 
Brain 3 (17.6) 6 
Breast 30 (15.2) 12 
Cancer of Unknown Primary 5 (25.0) 9 
Colon 60 (43.8) 21 
Leukaemia 7 (17.9) 5 
Liver 7 (14.0) 6 
Lung 95 (30.8) 51 
Lymphoma 16 (23.2) 9 
Melanoma 18 (24.0) 4 
Multiple Myeloma 4 (22.2) 3 
Oesophageal 17 (28.8) 4 
Oral 18 (40.9) 7 
Other 19 (25.7) 22 
Other Gynae 25 (39.1) 11 
Ovarian 12 (38.7) 7 
Pancreatic 8 (17.0) 8 
Prostate 67 (34.0) 25 
Rectal 27 (38.0) 2 
Renal 19 (32.2) 12 
Stomach 15 (32.6) 9 
NUMBER OF COMORBIDITIES   
None 99 (25.1) 81 
One Comorbidity 129 (27.4) 66 
Two Comorbidities 135 (32.3) 51 
Three of More Comorbidities 120 (31.7) 33 
REGIONAL CANCER NETWORK   
North 173 (28.7) 79 
West 261 (29.0) 112 
South East 51 (30.9) 45 
SIMD22   
1 (Most Deprived) 121 (32.3) 66 
2 83 (27.1) 45 
3 77 (27.4) 42 
4 110 (28.4) 44 
5 (Least Deprived) 94 (29.4) 39 
URBAN-RURAL 6-FOLD CLASSIFICATION   
Large Urban Area 188 (29.3) 101 
Other Urban Area 81 (21.3) 65 
Accessible Small Town 59 (33.3) 17 
Remote Small Town 20 (35.7) 17 
Accessible Rural Area 57 (28.2) 12 
Remote Rural Area 80 (37.7) 24 
URBAN-RURAL 2-FOLD CLASSIFICATION   
Urban 348 (27.7) 200 
Rural 137 (33.1) 36 
1n=1669, removing 109 screen detected and 236 “not known” cases
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Table 5: Number of primary care-led investigations ordered by the GP as part of the diagnostic assessment prior to referral (n=1954)1 
  Percentage of patients investigated by test type 














TOTAL 958 (49.0) 60 704 (36) 40 (2.0) 391 (20.0) 60 (3.1) 74 (3.8) 
GENDER        
Male 384 (39.8) 32 409 (42.3) 28 (2.9) 208 (21.5) 32 (3.3) 48 (5.0) 
Female 574  (58.1) 28 295 (29.9) 12 (1.2) 183 (18.5) 28 (2.8) 26 (2.6) 
AGE GROUP (YEARS)        
0-24 8 (53.3) 2 1 (6.7) 0 (0) 5 (33.3) 0 (0) 0 (0) 
25-49 113 (63.5) 6 36 (20.2) 4 (2.2) 25 (14.0) 5 (2.8) 14 (7.9) 
50-64 265 (52.6) 18 165 (32.7) 10 (2.0) 103 (20.4) 17 (3.4) 19 (3.8) 
65-74 235 (43.0) 17 222 (40.6) 8 (1.5) 126 (23.0) 17 (3.1) 19 (3.5) 
75-84 235 (46.2) 11 205 (40.3) 15 (2.9) 102 (20.0) 17 (3.3) 16 (3.1) 
>84 102 (50.7) 6 75 (37.3) 3 (1.5) 30 (14.9) 4 (2.0) 6 (3.0) 
CANCER-SITE        
Bladder 19 (38.8) 1 22 (44.9) 9 (18.4) 3 (6.1) 1 (2.0) 9 (18.4) 
Brain 13 (59.1) 1 6 (27.3) 0 (0) 1 (4.5) 1 (4.5) 0 (0) 
Breast 250 (95.1) 7 7 (2.7) 0 (0) 5 (1.9) 0 (0) 2 (0.8) 
Cancer of Unknown Primary 13 (44.8) 0 13 (448) 0 (0) 6 (20.7) 1 (3.4) 1 (3.4) 
Colon 87 (49.4) 7 83 (47.2) 1 (0.6) 17 (9.7) 11 (6.3) 4 (2.3) 
Leukaemia 17 (38.6) 0 26 (59.1) 0 (0) 5 (11.4) 0 (0) 0 (0) 
Liver 26 (48.1) 2 25 (46.3) 0 (0) 10 (18.5) 2 (3.7) 1 (1.9) 
Lung 134 (38.5) 11 123 (35.3) 2 (0.6) 179 (51.4) 5 (5.4) 8 (2.3) 
Lymphoma 28 (37.8) 4 39 952.7) 0 (0) 22 (29.7) 3 (4.1) 3 (4.1) 
Melanoma 65 (83.3) 1 3 (3.8) 0 (0) 1 (1.3) 0 (0) 0 (0) 
Multiple Myeloma 4 (19.0) 0 13 (61.9) 1 (4.8) 4 (19.0) 0 (0) 0 (0) 
Oesophageal 29 (47.5) 2 28 (45.9) 0 (0) 6 (9.8) 10 (16.4) 1 (1.6) 
Oral 37 (72.5) 0 11 (21.6) 0 (0) 6 (11.8) 0 (0) 2 (3.9) 
Other 28 (31.1) 6 30 (33.3) 3 (3.3) 34 (37.8) 1 (1.1) 3 (3.3) 
Other Gynae 47 (58.8) 3 17 (21.3) 4 (5.0) 13 (16.3) 2 (2.5) 7 (8.8) 
Ovarian 11 (31.4) 3 15 (42.9) 0 (0) 13 (37.1) 0 (0) 0 (0) 
Pancreatic 20 (37.0) 1 31 (57.4) 0 (0) 15 (27.8) 3 (5.6) 0 (0) 
Prostate 45 (21.0) 8 114 (53.3) 15 (7.0) 21 (9.8) 2 (0.9) 11 (5.1) 
Rectal 38 (43.2) 0 41 (46.6) 0 (0) 8 (9.1) 11 (12.5) 5 (5.7) 
Renal 32 (45.7) 1 25 (35.7) 5 (7.1) 15 (21.4) 0 (0) 6 (8.6) 
Stomach 15 (28.3) 2 32 (60.4) 0 (0) 7 (13.2) 7 (13.2) 2 (3.8) 
NUMBER OF COMORBIDITIES        
None 237 (48.0) 18 146 (29.6) 8 (1.6) 88 (17.8) 26 (5.3) 23 (4.7) 
One Comorbidity 282 (51.1) 21 208 (37.7) 12 (2.2) 112 (20.3) 10 (1.8) 20 (3.6) 
Two Comorbidities 237 (49.4) 12 179 (37.3) 9 (1.9) 97 (20.2) 15 (3.1) 21 (4.4) 
Three of More Comorbidities 196 (46.8) 5 169 (40.3) 11 (2.6) 92 (22.0) 9 (2.1) 10 (2.4) 
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REGIONAL CANCER NETWORK        
North 305 (42.8) 6 323 (45.4) 12 (1.7) 155 (21.8) 18 (2.5) 35 (4.9) 
West 543 (52.6) 46 319 (30.9) 27 (2.6) 201 (19.5) 35 (3.4) 34 (3.3) 
South East 110 (52.6) 8 62 (29.7) 1 (0.5) 35 (16.7) 7 (3.3) 5 (2.4) 
SIMD22        
1 (Most Deprived) 231 (52.4) 23 123 (27.9) 15 (3.4) 92 (20.9) 21 (4.8) 12 (2.7) 
2 181 (50.0) 12 136 (37.6) 4 (1.1) 75 (20.7) 6 (1.7) 9 (2.5) 
3 163 (49.4) 10 115 (34.8) 5 (1.5) 73 (22.1) 9 (2.7) 12 (3.6) 
4 200 (45.1) 9 183 (41.3) 11 (2.5) 87 (19.6) 12 (2.7) 22 (5.0) 
5 (Least Deprived) 183 (48.4) 6 147 (38.9) 5 (1.3) 64 (16.9) 12 (3.2) 19 (5.0) 
URBAN-RURAL 6-FOLD CLASSIFICATION        
Large Urban Area 395 (52.5) 28 246 (32.7) 19 (2.5) 139 (18.5) 24 (3.2) 16 (2.1) 
Other Urban Area 224 (49.1) 18 157 (34.4) 5 (1.1) 103 (22.6) 16 (3.5) 18 (3.9) 
Accessible Small Town 98 (47.6) 1 69 (33.5) 5 (2.4) 33 (16.0) 4 (1.9) 12 (5.8) 
Remote Small Town 33 (44.0) 2 32 (42.7) 1 (1.3) 15 (20.0) 2 (2.7) 5 (6.7) 
Accessible Rural Area 98 (45.4) 8 92 (42.6) 4 (1.9) 47 (21.8) 7 (3.2) 5 (2.3) 
Remote Rural Area 110 (44.2) 3 108 (43.4) 6 (2.4) 54 (21.7) 7 (2.8) 18 (7.2) 
URBAN-RURAL 2-FOLD CLASSIFICATION        
Urban 750 (50.4) 49 504 (33.8) 30 (2.0) 290 (19.5) 46 (3.1) 51 (3.4) 
Rural 208 (44.7) 11 200 (43.0) 10 (2.2) 101 (21.7) 14 (3.0) 23 (4.9) 
1n=1954 excluding 60 unknowns. Each patient could have > 1 investigation.  Number of investigations include Inapplicable and screening patients. 
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TABLE 6: Evidence of safety netting for patients presenting in primary care (n=1452)1 
 YES n (%) INAPPLICABLE n NOT KNOWN n 
TOTAL 535 (62.3) 429 164 
GENDER   63 
Male 278 (62.9) 203 81 
Female 257 (61.6) 226  
AGE GROUP (YEARS)    
0-24 3 (100) 3 2 
25-49 41 (57.7) 45 19 
50-64 128 (60.1) 106 41 
65-74 153 (61.2) 117 47 
75-84 161 (68.2) 103 38 
>84 49 (57.0) 55 17 
CANCER-SITE    
Bladder 20 (62.5) 5 5 
Brain 5 (100) 3 0 
Breast 38 (47.5) 82 16 
Cancer of Unknown Primary 11 (68.8) 4 1 
Colon 47 (56.6) 25 10 
Leukaemia 8 (66.7) 12 0 
Liver 9 (75.0) 14 7 
Lung 112 (64.7) 54 33 
Lymphoma 28 (73.7) 16 7 
Melanoma 10 (27.8) 15 8 
Multiple Myeloma 6 (85.7) 0 5 
Oesophageal 25 (75.8) 16 7 
Oral 11 (61.1) 14 4 
Other 22 (66.7) 25 9 
Other Gynae 16 (43.2) 17 8 
Ovarian 9 (69.2) 12 5 
Pancreatic 22 (81.5) 11 5 
Prostate 71 (64.5) 54 12 
Rectal 29 (64.4) 20 9 
Renal 17 (70.8) 11 5 
Stomach 19 (76.0) 9 8 
NUMBER OF COMORBIDITIES    
None 132 (65.7) 109 46 
One Comorbidity 133 (56.6) 134 43 
Two Comorbidities 139 (62.6) 108 33 
Three of More Comorbidities 129 (64.8) 73 42 
REGIONAL CANCER NETWORK    
North 191 (65.6) 200 43 
West 296 (59.3) 178 91 
South East 48 (69.6) 51 30 
SIMD22    
1 (Most Deprived) 121 (62.4) 84 4.8 
2 104 (62.7) 68 34 
3 86 (67.7) 86 25 
4 116 (58.6) 105 32 
5 (Least Deprived) 108 (62.1) 86 25 
URBAN-RURAL 6-FOLD CLASSIFICATION    
Large Urban Area 190 (62.9) 170 82 
Other Urban Area 140 (65.4) 88 40 
Accessible Small Town 56 (57.1) 44 11 
Remote Small Town 21 (100) 27 2 
Accessible Rural Area 63 (58.3) 49 15 
Remote Rural Area 65 (56.0) 51 13 
URBAN-RURAL 2-FOLD CLASSIFICATION    
Urban 407 (64.1) 329 136 
Rural 128 (57.1) 100 28 
1n=1452 excluding 164 “not knowns” and 429 inapplicable including 109 screening cases
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SUPPLEMENTARY TABLE 1: Sample composition and referral type that led most directly to the cancer diagnosis by country and gender 





















SCOTLAND 2014 753 (37.4) 186 (9.2) 207 (10.3) 119 (5.9) 402 (20.0) 22 (1.1) 167 (8.3) 158 (7.8) 
ENGLAND 17042 8820 (51.8) 745 (4.4) 1346 (7.9) 1237 (7.3) 2818 (16.5) 315 (1.8) 1004 (5.9) 757 (4.4) 
  p<0.001 p<0.001 p<0.001 p=0.073 p<0.001 p=0.030 p<0.001  
          
GENDER          
MALE 
(SCOTLAND) 
998 (49.6) 357 (35.8) 93 (9.3) 125 (12.5) 27 (2.7) 203 (20.3) 13 (1.3) 97 (9.7) 83 (8.3) 
MALE 
(ENGLAND) 
8544 (50.1) 4482 (52.5) 436 (5.1) 829 (9.7) 145 (1.7) 1474 (17.3) 187 (2.2) 549 (6.4) 442 (5.2) 
          
FEMALE 
(SCOTLAND) 
1016 (50.4) 396 (39.0) 93 (9.2) 82 (8.1) 92 (9.1) 199 (19.6) 9 (0.9) 70 (6.9) 75 (7.4) 
FEMALE 
(ENGLAND) 
8498 (49.9) 4338 (51.0) 309 (3.6) 517 (6.1) 1092 (12.9) 1344 (15.8) 128 (1.5) 455 (5.4) 315 (3.7) 
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SUPPLEMENTARY TABLE 2: Distribution of Primary Care Interval (PCI) and Diagnostic Interval (DI) by country and gender 
PRIMARY CARE INTERVAL 
 N 25th centile, days Median, days 75th centile, days % >60 days % > 90 days 
TOTAL       
SCOTLAND 1314 0 5 23 12.3 8.2 
ENGLAND 10493 0 5 27 12.5 9.2 
     p=0.214 P=0.477 
       
GENDER       
MALE (SCOTLAND) 656 0.75 8 28 12.3 8.2 
MALE (ENGLAND) 5478 0 8 30 13.7 9.2 
       
FEMALE (SCOTLAND) 658 0 2 19 10.2 7.1 
FEMALE (ENGLAND) 5015 0 1 21 11.2 7.3 
       
DIAGNOSTIC INTERVAL 
 N 25th centile, days Median, days 75th centile, days % >60 days % > 90 days 
TOTAL       
SCOTLAND 1572 13 30 68 28.3 17.8 
ENGLAND 12929 15 40 86 35.8 24.0 
     p<0.001 p<0.001 
       
GENDER       
MALE (SCOTLAND) 788 13 34 74 31.5 19.3 
MALE (ENGLAND) 6768 21 47 96 39.9 26.6 
       
FEMALE (SCOTLAND) 776 13 27 61 25.1 16.3 
FEMALE (ENGLAND) 6161 13 31 77 31.3 21.2 
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 AVOIDABLE DELAY n(%) NOT KNOWN n 
TOTAL   
SCOTLAND 485 (29.1) 236 
ENGLAND 3380 (22.0) 1673 
 p=0.239  
   
GENDER   
MALE (SCOTLAND) 251 (26.1) 124 
MALE (ENGLAND) 1839 (24.0) 897 
   
FEMALE (SCOTLAND) 231 (24.8) 112 
FEMALE (ENGLAND) 1541 (20.0) 776 
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SUPPLEMENTARY TABLE 4: Comparison of GP-led Investigations by country and gender 
  
















TOTAL        
SCOTLAND 958 (49.0) 60 704 (36.0) 40 (2.0) 391 (20.0) 60 (3.1) 74 (3.8) 
ENGLAND 9160 (54.6) 280 5795 (34.6) 212 (1.3) 3289 (19.6) 267 (1.6) 446 (2.7) 
 p<0.001  p=0.210 p=0.006 p=0.705 p<0.001 p=0.005 
        
GENDER        
MALE (SCOTLAND) 384 (39.8) 32 409 (42.3) 28 (2.9) 208 (21.5) 32 (3.3) 48 (5.0) 
MALE (ENGLAND) 3662 (43.7) 156 3773 (45.0) 152 (1.8) 1780 (21.2) 139 (1.7) 250 (3.0) 
        
FEMALE (SCOTLAND) 574 (58.1) 28 295 (29.9) 12 (1.2) 183 (18.5) 28 (2.8) 26 (2.6) 
FEMALE (ENGLAND) 5498 (65.7) 124 2022 (24.1) 60 (0.7) 1509 (18.0) 128 (1.5) 196 (2.3) 
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SUPPLEMENTARY TABLE 5: CHARACTERISTICS OF 77 PARTICIPATING GENERAL PRACTICES 
Practice Characteristic n(%) 
  
SIMD Deprivation Category  
SIMD 1 (Most Deprived) 20 (26.3) 
SIMD 2 21 (27.3) 
SIMD 3 10 (13.0) 
SIMD 4 16 (20.8) 
SIMD 5 (Least Deprived) 10 (13.0) 
  
Urban Rural – 2 Fold Classification  
Urban 57 (74.0) 
Rural 20 (26.0) 
  
Urban Rural – 6 Fold Classification  
Large Urban Area 26 (33.8) 
Other Urban Area 19 (24.7) 
Accessible Small Towns 7 (9.1) 
Remote Small Towns 5 (6.5) 
Accessible Rural Areas 3  (3.9) 
Remote Rural Areas 22.1) 
  
Mean List Size (SD) 5996.2 (4684.6)* 
Median List Size (IQR) 4741 (2774-8618) 
  
*Scottish Average List Size (2019) is 6171 patients (available at https://www.isdscotland.org/Health-Topics/General-Practice/Publications/data-
tables2017.asp). 
